Abbreviations

13vPCV 13 valent pneumococcal conjugate vaccine

23vPPV 23 valent pneumococcal polysaccharide vaccine

ABLV Australian bat lyssavirus

AFP acute flaccid paralysis

AGSP Australian Gonococcal Surveillance Programme

AIDS acquired immune deficiency syndrome

AMSP Australian Meningococcal Surveillance Programme

ANCJDR Australian National Creutzfeldt-Jakob Disease Registry

BCG bacille Calmette–Guérin

BFV Barmah Forest virus

CDI Communicable Diseases Intelligence

CDNA Communicable Diseases Network Australia

CDWG Case Definitions Working Group

CIDT culture-independent diagnostic testing

CJD Creutzfeldt-Jakob disease

CRS congenital rubella syndrome

DENV dengue virus

Hib Haemophilus influenzae type b

HIV human immunodeficiency virus

HPAIH highly pathogenic avian influenza in humans

HUS haemolytic uraemic syndrome

ILI influenza like illness

IMD invasive meningococcal disease

IPD invasive pneumococcal disease

JEV Japanese encephalitis virus

KUNV Kunjin virus

MMR measles-mumps-rubella

MVEV Murray Valley encephalitis virus

NAMAC National Arbovirus and Malaria Advisory Committee

NDP no data provided

NEC not elsewhere classified

NIP National Immunisation Program

NN not notifiable

Top of page

NNDSS National Notifiable Diseases Surveillance System

NQFMP National Q fever Management Program

NSC National Surveillance Committee

NS1 non-structural protein 1

PCR polymerase chain reaction

RRV Ross River virus

SACC Standard Australian Classification of Countries

SARS severe acute respiratory syndrome

STEC Shiga toxin-producing Escherichia coli

STI(s) sexually transmissible infections(s)

TB tuberculosis

VPD(s) vaccine preventable disease(s)

VZV varicella zoster virus

WHO World Health Organization

WHOCC World Health Organization Collaborating Centre for Reference and Research on Influenza

ZIKV Zika virus

Top of page

Acknowledgements

The authors wish to thank the following people for their contribution to this report.

Members of the National Surveillance Committee

The National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases

Author details

Coordinating author: Timothy Sloan-Gardner

Data management: Mark Trungove, Rachael Corvisy

Bloodborne diseases: Amy Bright, Carolyn Konrad

Gastrointestinal diseases: Timothy Sloan-Gardner

Quarantinable diseases: Katrina Knope

Sexually transmissible infections: Amy Bright, Amy Burroughs, Carolyn Konrad

Vaccine preventable diseases: Nicolee Martin, Anna Glynn-Robinson, Cindy Toms, Natasha Wood

Vectorborne diseases: Katrina Knope

Zoonoses: Timothy Sloan-Gardner

Other bacterial infections: Cindy Toms, Natasha Wood

Top of page

With contributions from:

National organisations

Communicable Diseases Network Australia and subcommittees

Australian Childhood Immunisation Register

Australian Gonococcal Surveillance Programme

Australian Meningococcal Surveillance Programme

Australian Sentinel Practice Research Network

Australian Quarantine Inspection Service

The Kirby Institute for Infection and Immunity in Society

National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases

National Enteric Pathogens Surveillance Scheme

OzFoodNet Working Group

World Health Organization Collaborating Centre for Reference and Research on Influenza

State and territory health departments

Communicable Diseases Control, ACT Health, Australian Capital Territory

Communicable Diseases Surveillance and Control Unit, NSW Ministry of Health, New South Wales

Centre for Disease Control, Northern Territory Department of Health and Community Services, Northern Territory

Communicable Diseases Branch, Queensland Health, Queensland

Communicable Disease Control, South Australian Department of Health, South Australia

Communicable Diseases Prevention Unit, Department of Health and Human Services, Tasmania

Health Protection Branch, Department of Health, Victoria

Communicable Diseases Control Directorate, Department of Health, Western Australia

Top of page

References

1. National Health Security Act, 2007. Accessed March 2015. Available from: http://www.legislation.gov.au/Details/C2007A00174
2. National Health Security (National Notifiable Disease List) Instrument 2008. Accessed March 2015. Available from: http://www.legislation.gov.au/ComLaw/legislation/LegislativeInstrument1.nsf/0/7162D634C6DD1BAACA25740B0079D6B8?OpenDocument
3. National Health Security Agreement 2008. Accessed March 2015. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-nhs-agreement.htm
4. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2015. UNSW Australia, Sydney NSW: The Kirby Institute; 2015.
5. Klug GM, Boyd A, Sarros S, Stehmann C, Simpson M, McLean CA, et al. Creutzfeldt-Jakob disease surveillance in Australia, update to December 2013. Commun Dis Intell 2014;38(4):E348–355.
6. Communicable Diseases Network Australia. National Notifiable Diseases Surveillance System. 2015. Accessed March 2015. Available from: www.health.gov.au/nndssdata
7. Australian Bureau of Statistics. Australian Demographic Statistics, December 2014. Canberra: Australian Bureau of Statistics; 2015. Report No.: ABS Catalogue: 3101.0.
8. Australian Institute of Health and Welfare. Age-standardised rate – Identifying and definitional attributes. 2005. Accessed on 17 March 2015. Available from: http://meteor.aihw.gov.au/content/index.phtml/itemId/327276
9. Graham S, Guy RJ, Donovan B, McManus H, El-Hayek C, Kwan K, et al. Epidemiology of chlamydia and gonorrhea among Indigenous and non-Indigenous Australians, 2000–2009. Med J Aust 2012;197(11):642–646.
10. Hammerschlag M. Sexually transmitted diseases in sexually abused children: medical and legal implications. Sex Transm Infect 1998;74(3):167–174.
11. Australian Institute of Health and Welfare. National Health Data Dictionary 13.3; 2008.
12. Australian Bureau of Statistics. Standard Australian Classification of Countries (SACC). Canberra: Australian Bureau of Statistics; 2011. Report No.: 1269.0.
13. Chen MY, Fairley CK, Donovan B. Nowhere near the point of diminishing returns: correlations between chlamydia testing and notification rates in New South Wales. Aust N Z J Public Health 2005;29(3):249–253.
14. Hocking J, Fairley C, Counahan M, Crofts N. The pattern of notification and testing for genital Chlamydia trachomatis infection in Victoria, 1998–2000: an ecological analysis. Aust N Z J Public Health 2003;27(4):405–408.
15. Burckhardt F, Warner P, Young H. What is the impact of change in diagnostic test method on surveillance data trends in Chlamydia trachomatis infection? Sex Transm Infect 2006;82(1):24–30.
16. Chen MY, Karvelas M, Sundararajan V, Hocking JS, Fairley CK. Evidence for the effectiveness of a chlamydia awareness campaign: increased population rates of chlamydia testing and detection. Int J STD AIDS 2007;18(4):239–243.
17. Hammad A, Guy RJ, Fairley C, Wand H, Chen MY, Dickson B, et al. Understanding trends in genital Chlamydia trachomatis can benefit from enhanced surveillance: findings from Australia. Sex Transm Infect 2012;88(7):552–557.
18. Stephens N, O’Sullivan M, Coleman D, Shaw K. Chlamydia trachomatis in Tasmania 2001–2007: rising notification trends. Aust N Z J Public Health 2010;34(2):120–125.
19. Communicable Diseases Network Australia. Australian national notifiable diseases case definitions. 2014. Accessed on 5 September 2014. Available from: http://www.health.gov.au/casedefinitions

Top of page

20. National HBV Testing Policy Expert Reference Committee. National hepatitis B testing policy 2012 v1.1. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Darlinghurst, NSW: Commonwealth of Australia; 2012.
21. National HCV Testing Policy Expert Reference Committee. National hepatitis C testing policy 2012 v1.1. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Darlinghurst, NSW: Commonwealth of Australia; 2012.
22. Heymann DL. Control of Communicable Diseases Manual. 19th edn. Washington: American Public Health Association, USA; 2008.
23. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases. Hepatitis B Vaccines for Australians: Information for Immunisation Providers. In; 2015.
24. Medicare Australia. Australian Childhood Immunisation Register – Statistics. 2014. Accessed March 2015. Available from: http://www.medicareaustralia.gov.au/provider/patients/acir/statistics.jsp
25. Gidding HF, Warlow M, MacIntyre CR, Backhouse J, Gilbert GL, Quinn HE, et al. The impact of a new universal infant and school-based adolescent hepatitis B vaccination program in Australia. Vaccine 2007;25(51):8637–8641.
26. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases. Accessed July 2014. Available from: http://www.ncirs.edu.au/provider-resources/vaccination-history/
27. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases. Hepatitis  vaccines for Australians, NCIRS fact sheet: June 2012. Accessed March 2015. Available from: http://www.ncirs.edu.au/assets/provider_resources/fact-sheets/hepatitis-B-fact-sheet.pdf
28. Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D, et al. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell 2010;34(Suppl):S1–S172.
29. Maclachlan JH, Towell T, Cowie BC. The burden of chronic hepatitis B virus infection in Australia, 2011. Aust N Z J Public Health 2013;37(5):416–422.
30. Naidu L, Chiu C, Habig A, Lowbridge C, Jayasinghe S, Wang H, et al. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006–2010. Commun Dis Intell 2013;37(Suppl):S1–S95.
31. Australian Bureau of Statistics. Census of Population and Housing: Characteristics of Aboriginal and Torres Strait Islander Australians, 2011, ABS. cat no 2076.0. Canberra: ABS; 2011.
32. Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. 10th edn. Canberra, Australia: National Health and Medical Research Council and the Department of Health; 2013.
33. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2014; 2014.
34. Butler T, Lim D, Callander D. National Prison Entrants’ Bloodborne Virus and Risk Behaviour Survey Report 2004, 2007 and 2010. Prevalence of HIV, hepatitis C, hepatitis B, sexually transmissible infections, and risk behaviours among Australian prison entrants; 2011.
35. Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 2007;91(2–3):228–235.
36. OzFoodNet Working Group. Monitoring the incidence and causes of diseases potentially transmitted by food in Australia: Annual report of the OzFoodNet network, 2011. Commun Dis Intell 2015;39(2):E236–264.
37. NNDSS Annual Report Writing Group. Australia’s notifiable disease status, 2013: Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2015;39(3):E387–E477.
38. Donnan EJ, Fielding JE, Gregory JE, Lalor K, Rowe S, Goldsmith P, et al. A multistate outbreak of hepatitis A associated with semidried tomatoes in Australia, 2009. Clin Infect Dis 2012;54(6):775–781.
39. New South Wales Ministry of Health. Health Protection Report, NSW – 2014. Accessed on 8 October 2015. Available from: http://www.health.nsw.gov.au/hpr/Pages/201502-diseases.aspx

Top of page

40. Lamont RF, Sobel J, Mazaki-Tovi S, Kusanovic JP, Vaisbuch E, Kim SK, et al. Listeriosis in human pregnancy: a systematic review. J Perinat Med 2011;39(3):227–236.
41. OzFoodNet Working Group. Monitoring the incidence and causes of diseases potentially transmitted by food in Australia: Annual report of the OzFoodNet Network, 2010. Commun Dis Intell 2012;36(3):E213–E241.
42. van den Beld MJ, Reubsaet FA. Differentiation between Shigella, enteroinvasive Escherichia coli (EIEC) and noninvasive Escherichia coli. Eur J Clin Microbiol Dis 2012;31(6):899–904.
43. Queensland Health. Statewide Weekly Communicable Diseases Surveillance Report 30 September 2013. Accessed on 7 October 2015. This document was available at the time of writing from: https://www.health.qld.gov.au/ph/documents/cdb/weeklyrprt-130930.pdf
44. Cumpston JHL. Health and disease in Australia. Canberra: Australian Government Publishing Service; 1989.
45. Grattan-Smith PJ O’Regan WJ, Ellis PS, O’Flaherty SJ, McIntyre PB, Barnes CJ. Rabies. A second Australian case with a long incubation period. Med J Aust 1992;156(9):651–654.
46. Fenner F, Henderson D, Arita I, Jezek Z, Ladnyi I. Smallpox and its eradication. Geneva, Switzerland; 1988.
47. Australian Government Department of Health and Ageing. Guidelines for smallpox outbreak, preparedness, response and management. 2004. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/health-pubhlth-publicat-document-metadata-smallpox.htm
48. Miller M, Roche P, Yohannes K, Spencer J, Bartlett M, Brotherton J, et al. Australia’s notifiable diseases status, 2003: Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2005;29(1):1–61.
49. World Health Organization. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. 2013. Available from: http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/index.html
50. Curran M, Harvey B, Crerar S. Annual report of the National Notifiable Diseases Surveillance System, 1996. Commun Dis Intell 1997;21:281–307.
51. Forssman B, Mannes T, Musto J, Gottlieb T, Robertson G, Natoli JD, et al. Vibrio cholerae O1 El Tor cluster in Sydney linked to imported whitebait. Med J Aust 2007;187(6):345–347.
52. Geisler W, Lensing S, Press C, Hook EW, 3rd. Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection. J Infect Dis 2013;207(12):1850–1856.
53. Victoria Department of Health. Blue book: Guidelines for the control of infectious diseases. 2009. Accessed on 3 April 2014. Available from: http://ideas.health.vic.gov.au/bluebook/
54. Australasian Society for HIV Medicine. HIV, viral hepatitis and STIs: a guide for primary care providers. Darlinghurst: Australasian Society for HIV Medicine; 2014.
55. Bowden FJ, on behalf of the National Donovanosis Eradication Advisory Committee. Donovanosis in Australia: going, going... Sex Transm Infect 2005;81(5):365–366.
56. Roberts-Witteveen A, Pennington K, Higgins N, Lang C, Lahra M, Waddell R, et al. Epidemiology of gonorrhoea notifications in Australia, 2007–12. Sex Health 2014;11(4):324–331.
57. Lahra M. Australian Gonococcal Surveillance Programme annual report, 2014. Commun Dis Intell 2015;39(3):E347–E354.
58. Prestage G, Ferris J, Grierson J, Thorpe R, Zablotska I, Imrie J, et al. Homosexual men in Australia: population, distribution and HIV prevalence. Sex Health 2008;5(2):97–102.
59. Allen K, Guy R, Leslie D, Goller J, Medland N, Roth N, et al. The rise of infectious syphilis in Victoria and the impact of enhanced clinical testing. Aust N Z J Public Health 2008;32(1):38–42.

Top of page

60. Australian Broadcasting Corporation. Mount Isa health unit battles rise in syphilis rates. 2014. Accessed on 27 July 2015. Available from: http://www.abc.net.au/news/2014–12–03/mount-isa-health-unit-not-expecting-short-term/5936434
61. Centre for Disease Control Northern Territory. Syphilis outbreak in the NT: 2015 update. The Northern Territory Disease Control Bulletin 2015;22(1):1–30.
62. Oaten J. Syphilis outbreak among Northern Territory Indigenous youth prompts fears for unborn children. 2015. Accessed on 28 July 2015. Available from: http://www.abc.net.au/news/2015–07–12/syphilis-outbreak-nt-indigenous-youth-prompts-fears-for-unborn/6613514
63. Baskin B. Queensland remote area health staff are struggling with a syphilis outbreak. The Daily Telegraph 7 August 2012.
64. Ward J, Guy RJ, Akre S, Middleton M, Giele C, Su J, et al. Epidemiology of syphilis in Australia: moving toward elimination of infectious syphilis from Aboriginal and Torres Strait Islander communities? Med J Aust 2011;194(10):525–529.
65. Australian Government Department of Health. Fourth National Aboriginal and Torres Strait Islander Blood-borne Viruses and Sexually Transmissible Infections Strategy, 2014–2014. Canberra: Australian Government Department of Health; 2014.
66. Australian Government Department of Health. Third National Sexually Transmissible Infections Strategy 2014–2017. Canberra: Australian Government Department of Health; 2014.
67. Impact of vaccines universally recommended for children. 1900–1998. MMWR Morb Mortal Wkly Rep 1999;48(12):243–248.
68. Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ 2008;86(2):81–60.
69. Ehreth J. The global value of vaccination. Vaccine 2003;21(7–8):596–600.
70. Préziosi M, Halloran ME. Effects of pertussis vaccination on disease: Vaccine efficacy in reducing clinical severity. Clin Infect Dis 2003;37(6):772–779.
71. Schlenker TL, Bain C, Baughman AL, Hadler SC. Measles herd immunity: the association of attack rates with immunization rates in preschool children. JAMA 1992;267(6):823–826.
72. Punpanich W, Chotpitayasunondh T. A review on the clinical spectrum and natural history of human influenza. Int J Infect Dis 2012;16(10):e714–e723.
73. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008;167:775–785.
74. Mauskopf J, Klesse M, Lee S, Herrera-Taracena G. The burden of influenza complications in different high-risk groups: a targeted literature review. J Med Econ 2013;16(2):264–277.
75. Bennett JE, Dolin R, Blaser MJ. Principles and Practice of Infectious Diseases. 8th edn: Elsevier Health Sciences; 2014.
76. de Jong MD, Thanh TT, Khanh TH, Hien VM, Smith GJD, Chau NV, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353(25):2667–2672.
77. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases. Haemophilus influenzae type b (Hib) vaccines for Australian children, NCIRS Fact sheet: October 2009. Sydney: National Centre for Immunisation Research and Surveillance for Vaccine Preventable Diseases; 2009.
78. Chandran A, Watt J, Santosham M. Haemophilus influenzae. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Philadelphia, PA, USA: Saunders Elsevier; 2008.
79. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases. Significant events in pneumococcal vaccination practice in Australia. 2015. Accessed on 26 May 2015. Available from: http://www.ncirs.edu.au/provider-resources/vaccination-history/

Top of page

80. Centers for Disease Control and Prevention. Measles. In: Atkinson W, Wolfe C, Hamborsky J, eds. Epidemiology and prevention of vaccine preventable diseases. 12th edn. Washington, D.C.: Public Health Foundation; 2011.
81. World Health Organization. Measles Fact Sheet Fact sheet N°286. Updated November 2015. Accessed November 2015. Available from: http://www.who.int/mediacentre/factsheets/fs286/en/
82. Strebel P, Papania M, Dayan G, Halsey N. Vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Philadelphia: Saunders Elsevier; 2008.
83. Heywood AE, Gidding HF, Riddell MA, McIntyre PB, MacIntyre CR, Kelly HA. Elimination of endemic measles transmission in Australia. Bull World Health Organ 2009;87(1):64–71.
84. Gidding H, Wood J, MacIntyre CR, Kelly H, Lambert SB, Gilbert GL, et al. Sustained measles elimination in Australia and priorities for long-term maintenance. Vaccine 2007;25(18):3574–3580.
85. Gidding HF, Gilbert GL. Measles immunity in young Australian adults. Commun Dis Intell 2001;25(3):133–136.
86. de Serres G, Gay NJ, Farrington CP. Epidemiology of transmissible diseases after elimination. Am J Epidemiol 2000;151(11):1039–1048.
87. World Health Organization. Four Western Pacific countries and areas are the first in their Region to be measles-free. 2014. Available from: http://www.wpro.who.int/mediacentre/releases/2014/20140320/en/
88. Plotkin SA, Rubin S. Mumps vaccine. 5th edn. Philadelphia, PA: Saunders Elsevier; 2008.
89. Deeks S, Lim G, Simpson M, Gagné L, Kristjanson E, Fung C, et al. An assessment of mumps vaccine effectiveness by dose during an outbreak in Canada. Can Med Assoc J 2011;183(9):1014–1020.
90. Demicheli V, Rivetti A, Debalini M, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Database Sys Rev 2012;2:CD004407.
91. Gupta R, Best J, MacMahon E. Mumps and the UK epidemic 2005. BMJ 2005;330:1132–1135.
92. Dayan GH, Quinlisk MP, Parker AA, Barskey AE, Harris ML, Schwartz JM, et al. Recent resurgence of mumps in the United States. N Engl J Med 2008;358(15):1580–1589.
93. Whelan J, Van Binnendijk R, Greenland K, Fanoy E, Kharqi M, Yap K, et al. Ongoing mumps outbreak in a student population with high vaccination coverage, Netherlands. Euro Surveill 2010;15(17):pii:19554.
94. Cohen C, White JM, Savage EJ, Glynn JR, Choi Y, Andrews N, et al. Vaccine effectiveness estimates, 2004–2005 mumps outbreak, England. Emerg Infect Dis 2007;13(1):12–17.
95. Pertussis. In: Atkinson W, Wolfe C, Hamborsky J, editors. Epidemiology and prevention of vaccine preventable diseases. 12th edn. Washington, DC: Public Health Foundation, Centers for Disease Control and Prevention; 2011.
96. Communicable Diseases Network Australia. Series of National Guidelines – Pertussis. 2013. Accessed March 2015. Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-song-pertussis.htm
97. Quinn H, McIntyre PB. Impact of removal of the 18 month DTPa dose on pertussis vaccine effectiveness. 12th National Immunisation Conference. Adelaide, South Australia; 2010.
98. Quinn HE, Snelling TL, Macartney KK, McIntyre PB. Duration of protection after first dose of acellular pertussis vaccine in infants. Pediatrics 2014;133(3):e513–e519.
99. Sheridan SL, McCall BJ, Davis CA, Robson JM, Hull BP, Selvey CE, et al. Acellular pertussis vaccine effectiveness for children during the 2009–2010 pertussis epidemic in Queensland. Med J Aust 2014;200(6):334–338.

Top of page

100. Wendelboe AM, van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005;24(5 Suppl):S58–S61.
101. Munoz FM. Pertussis in infants, children, and adolescents: diagnosis, treatment, and prevention. Semin Pediatr Infect Dis 2006;17(1):14–19.
102. McLean H, Redd S, Abernathy E, Icenogle J, Wallace G. Chapter 15: Congenital rubella syndrome. In: Manual for the Surveillance of Vaccine-Preventable Diseases. Atlanta: Centers for Disease Control and Prevention; 2012.
103. Song N, Gao Z, Wood J, Hueston L, Gilbert C, MacIntyre R, et al. Current epidemiology of rubella and congenital rubella syndrome in Australia: Progress towards elimination. Vaccine 2012;30(27):4073–4078.
104. Western Pacific Regional Office. Rubella and congenital rubella syndrome Geneva: World Health Organization; 2012.
105. Khandaker G, Zyrynski Y, Jones C. Surveillance for congenital rubella syndrome in Australia since 1993: cases reported between 2004 and 2013. Vaccine 2014;32(50):6746–6751.
106. Quinn H, McIntyre P. Tetanus in the elderly – An important preventable disease in Australia. Vaccine 2007;25(7):1304–1309.
107. Mackenzie JS, Lindsay MD, Coelen RJ, Broom AK, Hall RA, Smith DW. Arboviruses causing human disease in the Australasian zoogeographic region. Arch Virol 1994;136(3–4):447–467.
108. Russell RC, Dwyer DE. Arboviruses associated with human disease in Australia. Microbes Infect 2000;2(14):1693–1704.
109. Viennet E, Knope K, Faddy H, Williams C, Harley D. Assessing the threat of chikungunya emergence in Australia. Commun Dis Intell 2013;37(2):E136–E143.
110. Knope K, Kurucz N, Doggett S, Muller M, Johansen C, Feldman R, et al. Arboviral diseases and malaria in Australia, 2012–13: annual report of the National Arbovirus and Malaria Advisory Committee. Commun Dis Intell 2016;40(1):E17–E47.
111. Communicable Diseases Network Australia. Australian National Notifiable Diseases case definitions. 2014. Accessed on 5 September 2015. Available from: http://www.health.gov.au/casedefinitions
112. Therapeutic Goods Administration. Product recall, Panbio Barmah Forest virus IgM ELISA. An in vitro diagnostic medical device (IVD). Recall no. RC-2013-RN-00967-1,13/09/2013. 2013. Accessed on 6 May 2014. Available from: http://www.tga.gov.au/SARA/arn-detail.aspx?k=RC-2013-RN-00967-1
113. Rich G, McKechnie J, McPhan I, Richards B. Laboratory diagnosis of Ross River virus infection. Commun Dis Intell 1993;17(10):208–209.
114. Selvey LA, Donnelly JA, Lindsay MD, Pottumarthy Boddu S, D’Abrera VC, Smith DW. Ross River virus infection surveillance in the Greater Perth Metropolitan Area – has there been an increase in cases in the winter months? Commun Dis Intell 2014;38(2):E114–E122.
115. Guzman MG, Kouri G, Martinez E, Bravo J, Riveron R, Soler M, et al. Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Bull Pan Am Health Organ 1987;21(3):270–279.
116. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000;181(1):2–9.
117. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004;10(12 Suppl):S98–S109.
118. Souarès Y, Pacific Public Health Surveillance Network. Telehealth and outbreak prevention and control: the foundations and advances of the Pacific Public Health Surveillance Network. Pac Health Dialog 2000;7(2):11–28.
119. Hanna JN, Ritchie SA, Richards AR, Humphreys JL, Montgomery BL, Ehlers GJ, et al. Dengue in north Queensland, 2005–2008. Commun Dis Intell 2009;33(2):198–203.

Top of page

120. Queensland Health. Queensland Dengue Management Plan 2010–2015, 2011. Queensland: Queensland Health.
121. Knope K, National Arbovirus and Malaria Advisory Committee, Giele C. Increasing notifications of dengue related to overseas travel, 1991 to 2012. Commun Dis Intell 2013;37(1):E55–E59.
122. Hanna JN, Ritchie SA, Phillips DA, Lee JM, Hills SL, van den Hurk AF, et al. Japanese encephalitis in north Queensland, Australia, 1998. Med J Aust 1999;170(11):533–536.
123. Knope K, Whelan P, Smith D, Johansen C, Moran R, Doggett S, et al. Arboviral diseases and malaria in Australia, 2010–11: annual report of the National Arbovirus and Malaria Advisory Committee. Commun Dis Intell 2013;37(1):E1–E20.
124. Knox J, Cowan R, Doyle J, Ligtermoet M, Archer J, Burrow J, et al. Murray Valley encephalitis: a review of clinical features, diagnosis and treatment. Med J Aust 2012;196(5):322–326.
125. Roche S, Wicks R, Garner M, East IJ, Paskin R, Moloney BJ, et al. Descriptive overview of the 2011 epidemic of arboviral disease in horses in Australia. Aust Vet J 2013;91(1–2):5–13.
126. Frost MJ, Zhang J, Edmonds JH, Prow NA, Gu X, Davis R, et al. Characterization of virulent West Nile virus Kunjin strain, Australia, 2011. Emerg Infect Dis 2012;18(5):792–800.
127. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008;46(2):165–171. doi: 110.1086/524888.
128. World Health Organization. Synopsis of the world malaria situation in 1981. Wkly Epidemiol Rec 1983;58(26):197–199.
129. Leder K, Torresi J, Brownstein JS, Wilson ME, Keystone JS, Barnett E, et al. Travel-associated illness trends and clusters, 2000–2010. Emerg Infect Dis 2013;19(7):1049–1073.
130. Gray TJ, Trauer JM, Fairley M, Krause VL, Markey PG. Imported malaria in the Northern Territory, Australia—428 consecutive cases. Commun Dis Intell 2012;36(1):107–113.
131. Hanna JN, Ritchie SA, Eisen DP, Cooper RD, Brookes DL, Montgomery BL. An outbreak of Plasmodium vivax malaria in Far North Queensland, 2002. Med J Aust 2004;180(1):24–28.
132. World Health Organization. Zoonoses. Technical report series no. 169. Geneva, Switzerland: World Health Organization; 1959.
133. Taylor LH, Latham SM, Woolhouse ME. Risk factors for human disease emergence. Philos Trans R Soc Lond B Biol Sci 2001;356(1411):983–989.
134. Jones KE, Patel NG, Levy MA. Global trends in emerging infectious diseases. Nature 2008(451):990–994.
135. Woolhouse MEJ, Gowtage-Sequeria S. Host range and emerging and re-emerging pathogens. Emerg Infect Dis 2005;11(12):1842–1847.
136. World Health Organization. Report of the WHO/FAO/OIE joint consultation on emerging zoonotic diseases. Geneva, Switzerland: World Health Organization; 2004.
137. Animal Health Australia. Animal Health in Australia, 2014. Canberra: Animal Health Australia; 2015.
138. Kolbe A, Yuen M, Doyle B. A case of human cutaneous anthrax. Med J Aust 2006;185(5):281–282.
139. Fielding J. Zoonoses: Anthrax. Victorian Infectious Diseases Bulletin 2007;10(2):47.

Top of page

140. NSW Department of Health. Communicable Diseases Report, NSW, January and February 2010. N S W Public Health Bull 2010;21(3–4):103–107.
141. Calisher CH, Ellison JA. The other rabies viruses: The emergence and importance of lyssaviruses from bats and other vertebrates. Travel Med Infect Dis 2012;10(2):69–79.
142. Fraser GC, Hooper PT, Lunt RA, Gould AR, Gleeson LJ, Hyatt AD, et al. Encephalitis caused by a lyssavirus in fruit bats in Australia. Emerg Infect Dis 1996;2(4):327–331.
143. Hooper PT, Lunt RA, Gould AR, Samaratunga H, Hyatt AD, Gleeson LJ, et al. A new lyssavirus — the first endemic rabies-related virus recognized in Australia. Bulletin de l’Institut Pasteur 1997;95(4):209–218.
144. Communicable Diseases Network Australia. Series of National Guidelines: Rabies virus and other lyssavirus including Australian bat lyssavirus) exposures and infections. 2013. Accessed on 7 June 2015. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-song-abvl-rabies.htm
145. Allworth A, Murray K, Morgan J. A human case of encephalitis due to a lyssavirus recently identified in fruit bats. Commun Dis Intell 1996;20(24):504.
146. Hanna JN, Carney IK, Smith GA, Tannenberg AEG, Deverill JE, Botha JA, et al. Australian bat lyssavirus infection: a second human case, with long incubation period. Med J Aust 2000;172(12):597–599.
147. Francis JR, Nourse C, Vaska VL, Calvert S, Northill JA, McCall B, et al. Australian bat lyssavirus in a child: The first reported case. Pediatrics 2014;133(4):e1063–1067.
148. Queensland Department of Agriculture. Australian bat lyssavirus overview. In: Animal Health and Diseases: Queensland Government; 2013.
149. Crook A. Australian bat lyssavirus communiqué. Department of Agriculture, Fisheries and Forestry; 2013.
150. Bat Health Focus Group. ABLV Bat Stats, Australian Bat Lyssavirus report – December 2014. Wildlife Health Australia 2015.
151. Eales KM, Norton RE, Ketheesan N. Brucellosis in northern Australia. Am J Trop Med Hyg 2010;83(4):876–878.
152. Levett PN. Leptospirosis. Clin Microbiol Rev 2001;14(2):296–326.
153. World Health Organization, Society IL. Human Leptospirosis: Guidance for Diagnosis, Surveillance and Control; 2003.
154. O’Leary FM, Hunjan JS, Bradbury R, Thanakrishnan G. Fatal leptospirosis presenting as musculoskeletal chest pain. Med J Aust 2004;180(1):29–31.
155. Beeckman DS, Vanrompay DC. Zoonotic Chlamydophila psittaci infections from a clinical perspective. Clin Microbiol Infect 2009;15(1):11–17.
156. Deschuyffeleer TP, Tyberghien LF, Dickx VL, Geens T, Saelen JM, Vanrompay DC, et al. Risk assessment and management of Chlamydia psittaci in poultry processing plants. Ann Occup Hyg 2012;56(3):340–349.
157. McCaul TF, Williams JC. Developmental cycle of Coxiella burnetii: structure and morphogenesis of vegetative and sporogenic differentiations. J Bacteriol 1981;147(3):1063–1076.
158. Lowbridge CP, Tobin S, Seale H, Ferson MJ. Notifications of Q fever in NSW, 2001–2010. N S W Public Health Bull 2012;23(1–2):31–35.
159. Bell M, Patel M, Sheridan J. Q fever vaccination in Queensland abattoirs. Commun Dis Intell 1997;21(3):29–31.

Top of page

160. Lin M, Delpech V, McAnulty J, Campbell-Lloyd S. Notifications of Q fever in New South Wales, 1991–2000: EpiReview. N S W Public Health Bull 2001;12(6):172–175.
161. Gidding HF, Wallace C, Lawrence GL, McIntyre PB. Australia’s National Q Fever Vaccination Program. Vaccine 2009;27(14):2037–2041.
162. Ellis J, Oyston PC, Green M, Titball RW. Tularemia. Clin Microbiol Rev 2002;15(4):631–646.
163. Jackson J, McGregor A, Cooley L, Ng J, Brown M, Ong CW, et al. Francisella tularensis subspecies holarctica, Tasmania, Australia, 2011. Emerg Infect Dis 2012;18(9):1484–1486.
164. Veitch M. The public health response to tularaemia in Tasmania. Communicable Disease Control Conference 2013. Canberra, Australia; 2013.
165. NNDSS Annual Report Writing Group. Australia’s notifiable disease status, 2011: Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2013;37(4):E313–E393.
166. de Jong B. Legionella, springtime and potting soils. Euro Surveill 2010;15(8):19497.
167. O’Connor BA, Carman J, Eckert K, Tucker G, Givney R, Cameron S. Does potting mix make you sick? Results for a Legionella longbeachae case–control study in South Australia. Epidemiol Infect 2007;135(1):34–39.
168. Pravinkumar SJ, Edwards G, Lindsay D, Redmond S, Stirling J, House R, et al. A cluster of Legionnaires’ disease caused by Legionella longbeachae linked to potting compost in Scotland, 2008–2009. Euro Surveill 2010;15(8):19496.
169. Whiley H, Bentham R. Legionella longbeachae and legionellosis. Emerg Infect Dis 2011;17(4):579–583.
170. Li J, O’Brien ED, Guest C. A review of national legionellosis surveillance in Australia, 1991 to 2000. Commun Dis Intell 2002;26:462–470.
171. Rota MC, Caporal MG, Bella A, Ricci ML, Napoli C. Legionnaires disease in Italy: results of the epidemiological surveillance from 2000 to 2011. Euro Surveill 2013;18(23).
172. World Health Organization. Leprosy – Fact Sheet No. 101. 2015. Accessed on 19 June 2015. Available from: http://www.who.int/mediacentre/factsheets/fs101/en/
173. Communicable Diseases Network Australia. Meningococcal disease (invasive) surveillance case definition – V1.4. 2009. Accessed on 6 July 2015. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_mening.htm
174. Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, et al. Global Epidemiology of invasive meningococcal disease. Population Health Metrics 2013;11(17).
175. Lahra MM, Enriquez R. Annual Report of the Australian Meningococcal Surveillance Programme, 2014. Commun Dis Intell 2016. In press.
176. Bareja C, Waring J, Stapledon R, National Tuberculosis Advisory Committee for the Communicable Diseases Network Australia. Tuberculosis notifications in Australia, 2010. Commun Dis Intell 2014;38(1):E36–E48.
177. Luca S, Mihaescu T. History of BCG Vaccine. Maedica (Burchar) 2013;8(1):53–58.
178. Public Health England. Tuberculosis: the green book, chapter 32. In: Immunisation against infectious disease London: Department of Health; 2013. p. 394.
179. National Tuberculosis Advisory Committee. The BCG vaccine: Information and recommendations for use in Australia. Commun Dis Intell 2013;37(1):E65–E72.

Top of page